48 results
8-K
EX-99.1
TSHA
Taysha Gene Therapies Inc
19 Mar 24
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
4:17pm
vg following review of initial clinical data from the six-week post-treatment assessment.
Received authorization from U.K. Medicines and Healthcare … from the U.K. Medicines and Healthcare Products Regulatory Agency.
About Rett Syndrome
Rett syndrome is a rare neurodevelopmental disorder caused
8-K
EX-99.1
TSHA
Taysha Gene Therapies Inc
10 Jan 24
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
12:00am
three female patients 5-8 years of age with Rett syndrome. The Company also announced the United Kingdom (U.K.) Medicines and Healthcare products
8-K
EX-99.1
TSHA
Taysha Gene Therapies Inc
14 Nov 23
Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
4:47pm
. anticipated in the first quarter of 2024
U.K. Medicines and Healthcare products Regulatory Agency (MHRA) response to Clinical Trial Application (CTA
8-K
EX-99.1
xnfbh814
26 Sep 23
Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome
8:08am
424B3
t73y6hx4
11 Sep 23
Prospectus supplement
4:01pm
8-K
EX-99.2
uq50z34x xqkujwn
14 Aug 23
Entry into a Material Definitive Agreement
7:29am
8-K
EX-10.1
xznem
14 Aug 23
Entry into a Material Definitive Agreement
7:29am
8-K
EX-99.1
how5cs68o3f2t
14 Aug 23
Entry into a Material Definitive Agreement
7:29am
8-K
isjesn
22 Jun 23
Departure of Directors or Certain Officers
5:12pm
8-K
EX-99.1
hb84tfdutt9i gf2wg6
5 Jun 23
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial
8:20am
424B3
nykc1i 3lh0k9
4 May 23
Prospectus supplement
4:02pm